REGN stock price reacted positively to updated guidance, jumping 1.2% to $939.88 in midday trading. Increased analyst coverage now places average target price at $975, indicating upside potential over the next 6–12 months. Recently, UBS ( NYSE:UBS ) initiated BHVN stock at a Buy, praising its “diverse set of innovative programs” and potential for its obesity drug. I couldn’t agree more. BioHaven may very well be one of the most exciting (and innovative) biotech lightweights on the market right now. The firm has the potential to make a massive splash if any one of its innovations turns into a blockbuster. That alone makes BHVN stock worth watching, if not buying, following the latest 13% pullback off highs. To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. REGN stock price continues to attract option traders, with open interest rising 18% in bullish contracts. This positioning suggests the market is bracing for a possible upside surprise from upcoming FDA review decisions.
